# The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy

## TL;DR

This review discusses how to manage heart failure and comorbidities in patients with transthyretin amyloid cardiomyopathy, emphasizing the need for tailored treatment strategies.

## Contribution

The paper highlights the importance of integrating comorbidity care into the treatment of ATTR-CM for improved patient outcomes.

## Key findings

- ATTR-CM is now more commonly diagnosed due to increased awareness and non-invasive diagnostic methods.
- Patients with ATTR-CM often have multiple comorbidities, which may affect treatment response and outcomes.
- Earlier diagnosis and real-world evidence are crucial for improving prognosis and guiding future research.

## Abstract

This review aims to provide an updated overview of the clinical management of heart failure and comorbidities in transthyretin amyloid cardiomyopathy (ATTR-CM). We sought to address key unanswered questions and current uncertainties regarding treatment response, prognosis, and optimization of care in this complex population.

Once considered rare, ATTR-CM is now increasingly recognized due to greater awareness and the possibility of non-invasive diagnosis. Patients are often identified at earlier stages, with lower mortality than historically observed. Disease-modifying therapies with proven efficacy in randomized trials are now available, yet many patients experience disease progression. In real-world practice, ATTR-CM patients are typically older and have multiple cardiac and extracardiac comorbidities, often representing exclusion criteria of clinical trials, which may influence treatment response and efficacy.

Modern management of ATTR-CM should integrate heart failure treatment with tailored approaches to comorbidity care. Earlier diagnosis, real-world evidence, and strategies for patients outside trial populations will be essential to improve prognosis and guide future research.